CoChat
Sign Up
Cited by 133Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesSchizophrenia research and treatment

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Open access
Carey, Paul D, Vythilingum, Bavanisha, Seedat, Soraya, Muller, Jacqueline E, van Ameringen, Michael, Stein, Dan J·2005·BMC Psychiatry
DOI 10.1186/1471-244x-5-5PMC PMC547907
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Although serotonin reuptake inhibitors are effective in the treatment of OCD, many patients fail to respond to these agents. Growing evidence from open-label and placebo-controlled trials suggests a role for augmentation of SRIs with atypical antipsychotics in OCD. Quetiapine is generally well tolerated and previous open-label data has produced mixed results in OCD and additional controlled data is needed. Methods: We undertook a double-blind, randomised, parallel-group, flexible-dose, placebo-controlled study of quetiapine augmentation in subjects who had responded inadequately to open-label treatment with an SRI for 12 weeks. Following informed consent and screening, forty-two subjects were randomised to either placebo or quetiapine for six weeks. Results: There was significant improvement from baseline to endpoint on the Yale-Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p < 0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo treated subjects being classified as responders. Quetiapine did not demonstrate a significant benefit over placebo at the end of the six-week treatment period (p = .636). Similarly quetiapine failed to separate from placebo in the subgroup of subjects (n = 10) with co-morbid tics. Quetiapine was generally well tolerated. Conclusions: In this study, quetiapine augmentation was no more effective than placebo augmentation of SRIs. A number of limitations in study design make comparisons with previous studies in this area difficult and probably contributed to our negative findings. Future work in this important clinical area should address these limitations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-244x-5-5

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Second-generation antipsychotic agents have shown benefit in OCD, either alone or as adjunctive therapy; high-dose olanzapine, quetiapine, and risperidone have all shown at least minimal clinical benefit relative to placebo.

    “Recently, second-generation antipsychotic agents have shown benefit, either alone or as adjunctive therapy. Specifically, high-dose olanzapine [522], quetiapine [523], and risperidone [524] have all shown at least minimal clinical benefit relative to placebo treatment [525].”

    From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [523]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Diagnostic and Statistical Manual for Mental Disorders Fourth Edition TR 2002 Washington, D.C., American Psychiatric Association

Cited by

Sorted by citations

Related

Authors
Carey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J.
Affiliations
Stellenbosch University (ZA)
Corresponding author
Carey, Paul D
ORCID
Venue
BMC Psychiatry
Publisher
Springer Science and Business Media LLC
Published
2005-01-24
Volume
5
Issue
1
Pages
5-5
ISSN
1471-244X (ISSN-L)
DOI
10.1186/1471-244x-5-5
PMC
PMC547907
OpenAlex
W2128853507
Cited by
133
References
37
Citations by year
2026: 4 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 1 · 2020: 4 · 2019: 7 · 2018: 6 · 2017: 3 · 2016: 7 · 2015: 7 · 2014: 9 · 2013: 4 · 2012: 8
FWCI
15.04
Type
journal article
Language
en
Update notices
erratum (2005-11-30)
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • SUNScholar (Stellenbosch University) (submittedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
quetiapine, obsessive-compulsive disorder, treatment-refractory OCD, serotonin reuptake inhibitors, drug augmentation, atypical antipsychotics, Yale-Brown Obsessive Compulsive Scale, drug tolerability
MeSH terms
Quetiapine Fumarate, Adolescent, Adult, Dibenzothiazepines, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Placebos, Psychiatric Status Rating Scales, Antipsychotic Agents, Treatment Outcome, Treatment Failure, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review